RA Capital Management - Q2 2024 holdings

$7.56 Billion is the total value of RA Capital Management's 79 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 26.3% .

 Value Shares↓ Weighting
ASND  ASCENDIS PHARMA A/S - ADRsh$1,378,583,592
-9.8%
10,108,4000.0%18.23%
-6.2%
PCVX  VAXCYTE INCsh$619,465,465
+10.5%
8,203,7540.0%8.19%
+14.9%
JANX  JANUX THERAPEUTICS INCsh$383,949,162
+11.3%
9,165,6520.0%5.08%
+15.7%
LEGN BuyLEGEND BIOTECH CORP-ADRsh$332,482,107
-13.6%
7,506,934
+9.4%
4.40%
-10.2%
RYTM BuyRHYTHM PHARMACEUTICALS INCsh$249,825,957
+8.2%
6,084,412
+14.1%
3.30%
+12.5%
BIIB BuyBIOGEN INCsh$227,679,463
+42.5%
982,139
+32.6%
3.01%
+48.2%
BuyELIEM THERAPEUTICS INCsh$223,390,988
+520.0%
31,419,267
+138.9%
2.96%
+545.2%
BuyRXSIGHT INCsh$222,317,620
+25.2%
3,694,825
+7.3%
2.94%
+30.1%
RNA BuyAVIDITY BIOSCIENCES INCsh$220,606,667
+163.4%
5,400,408
+64.5%
2.92%
+173.7%
DYN BuyDYNE THERAPEUTICS INCsh$213,476,409
+51.8%
6,049,204
+22.1%
2.82%
+57.7%
GERN  GERON CORPsh$195,898,282
+28.5%
46,202,4250.0%2.59%
+33.6%
 PEPGEN INCsh$170,605,138
+8.6%
10,689,5450.0%2.26%
+12.9%
 TYRA BIOSCIENCES INCsh$166,561,578
-2.5%
10,416,6090.0%2.20%
+1.4%
EVH BuyEVOLENT HEALTH INC - Ash$162,804,161
-13.4%
8,514,862
+48.4%
2.15%
-10.0%
EWTX  EDGEWISE THERAPEUTICS INCsh$160,452,729
-1.3%
8,909,0910.0%2.12%
+2.7%
BuyNEWAMSTERDAM PHARMA CO NVsh$154,909,440
-16.7%
8,064,000
+2.5%
2.05%
-13.4%
RXRX NewRECURSION PHARMACEUTICALS-Ash$115,384,61315,384,615
+100.0%
1.53%
ETNB Buy89BIO INCsh$113,544,938
-23.6%
14,175,398
+11.0%
1.50%
-20.6%
VRNA BuyVERONA PHARMA PLC - ADRsh$110,368,061
+8.6%
7,632,646
+20.8%
1.46%
+12.9%
DAWN BuyDAY ONE BIOPHARMACEUTICALS Ish$108,472,315
-15.9%
7,871,721
+0.8%
1.44%
-12.6%
FDMT Buy4D MOLECULAR THERAPEUTICS INsh$107,011,449
-33.5%
5,098,211
+0.9%
1.42%
-30.9%
SBTX  ARS PHARMACEUTICALS INCsh$92,426,914
-16.7%
10,860,9770.0%1.22%
-13.5%
WVE  WAVE LIFE SCIENCES LTDsh$90,828,025
-19.1%
18,202,0090.0%1.20%
-16.0%
LBPH  LONGBOARD PHARMACEUTICALS INsh$88,904,887
+25.1%
3,289,1190.0%1.18%
+30.1%
NewARCELLX INCsh$88,525,5331,604,014
+100.0%
1.17%
AXSM  AXSOME THERAPEUTICS INCsh$80,500,000
+0.9%
1,000,0000.0%1.06%
+4.9%
SellAPOGEE THERAPEUTICS INCsh$77,199,309
-41.3%
1,961,863
-0.8%
1.02%
-38.9%
GHRS BuyGH RESEARCH PLCsh$76,975,694
+15.5%
6,601,689
+5.6%
1.02%
+20.0%
BuySTRUCTURE THERAPEUTICS INCsh$74,486,236
+15.1%
1,896,772
+25.6%
0.98%
+19.5%
 LENZ THERAPEUTICS INCsh$72,251,850
-22.6%
4,178,8230.0%0.96%
-19.5%
FULC  FULCRUM THERAPEUTICS INCsh$71,980,165
-34.3%
11,609,7040.0%0.95%
-31.7%
NKTX  NKARTA INCsh$63,858,312
-45.3%
10,805,1290.0%0.84%
-43.1%
 DIANTHUS THERAPEUTICS INCsh$60,378,040
-13.7%
2,333,0000.0%0.80%
-10.2%
 MINERALYS THERAPEUTICS INCsh$56,756,513
-9.4%
4,850,9840.0%0.75%
-5.8%
ITOS SellITEOS THERAPEUTICS INCsh$52,196,124
-13.4%
3,517,259
-20.4%
0.69%
-10.0%
URGN  UROGEN PHARMA LTDsh$51,739,955
+11.9%
3,083,4300.0%0.68%
+16.3%
BuyPRAXIS PRECISION MEDICINES Ish$51,104,375
+1.1%
1,235,599
+49.2%
0.68%
+5.1%
 ENLIVEN THERAPEUTICS INCsh$49,602,007
+32.9%
2,122,4650.0%0.66%
+38.1%
BuyACRIVON THERAPEUTICS INCsh$48,374,946
+40.6%
8,340,508
+73.4%
0.64%
+46.1%
BuyASTRIA THERAPEUTICS INCsh$45,898,180
-26.1%
5,043,756
+14.3%
0.61%
-23.2%
BCYC BuyBICYCLE THERAPEUTICS PLC-ADRsh$45,600,720
+128.9%
2,253,000
+181.6%
0.60%
+138.3%
 CG ONCOLOGY INCsh$44,116,960
-28.1%
1,397,4330.0%0.58%
-25.3%
LRMR  LARIMAR THERAPEUTICS INCsh$43,828,795
-4.5%
6,045,3510.0%0.58%
-0.7%
ABOS  ACUMEN PHARMACEUTICALS INCsh$36,135,592
-40.2%
14,932,0630.0%0.48%
-37.8%
NewTOURMALINE BIO INCsh$32,650,5762,538,925
+100.0%
0.43%
 THIRD HARMONIC BIO INCsh$26,429,728
+37.7%
2,033,0560.0%0.35%
+43.4%
 SOLID BIOSCIENCES INCsh$24,553,629
-57.4%
4,330,4460.0%0.32%
-55.7%
TSHA  TAYSHA GENE THERAPIES INCsh$24,354,407
-22.0%
10,872,5030.0%0.32%
-18.9%
BuyTENAYA THERAPEUTICS INCsh$23,629,276
-21.5%
7,622,347
+32.4%
0.31%
-18.3%
VOR  VOR BIOPHARMA INCsh$22,748,880
-57.8%
22,748,8800.0%0.30%
-56.1%
CCCC  C4 THERAPEUTICS INCsh$22,536,360
-43.5%
4,878,0000.0%0.30%
-41.2%
BuyALTO NEUROSCIENCE INCsh$22,294,572
+4.8%
2,085,554
+50.5%
0.30%
+8.9%
IMTX  IMMATICS NVsh$20,335,000
+10.6%
1,750,0000.0%0.27%
+15.0%
BuySERA PROGNOSTICS INC-Ash$17,954,223
-2.5%
3,032,808
+49.8%
0.24%
+1.3%
AVTE BuyAEROVATE THERAPEUTICS INCsh$15,258,873
-93.8%
9,192,092
+11.2%
0.20%
-93.5%
HOWL  WEREWOLF THERAPEUTICS INCsh$14,993,510
-62.3%
6,144,8810.0%0.20%
-60.9%
SellCERVOMED INCsh$13,989,094
-30.3%
817,120
-5.2%
0.18%
-27.5%
PLRX  PLIANT THERAPEUTICS INCsh$13,770,750
-27.9%
1,281,0000.0%0.18%
-25.1%
NRIX NewNURIX THERAPEUTICS INCsh$13,565,500650,000
+100.0%
0.18%
INSM NewINSMED INCsh$13,400,000200,000
+100.0%
0.18%
CLXPF SellCYBIN INCsh$11,925,210
-50.4%
44,004,464
-24.3%
0.16%
-48.4%
 AN2 THERAPEUTICS INCsh$11,935,284
-33.8%
5,551,2950.0%0.16%
-31.3%
NewZURA BIO LTDsh$11,261,2613,217,503
+100.0%
0.15%
 REGULUS THERAPEUTICS INCsh$11,156,250
-38.0%
6,250,0000.0%0.15%
-35.4%
ARVN  ARVINAS INCsh$11,216,284
-35.5%
421,3480.0%0.15%
-33.0%
BuyLEXEO THERAPEUTICS INCsh$10,790,300
+4.1%
672,712
+1.8%
0.14%
+8.3%
ACET  ADICET BIO INCsh$9,124,610
-48.5%
7,541,0000.0%0.12%
-46.2%
NewNUVALENT INC-Ash$9,087,194119,789
+100.0%
0.12%
MGNX  MACROGENICS INCsh$8,848,589
-71.1%
2,082,0210.0%0.12%
-70.0%
 BOUNDLESS BIO INCsh$8,439,042
-72.8%
2,180,6310.0%0.11%
-71.6%
CMRX  CHIMERIX INCsh$7,708,800
-17.4%
8,800,0000.0%0.10%
-14.3%
NewPERCEPTIVE CAPITAL SOLUTIONSsh$7,545,000750,000
+100.0%
0.10%
SellMETAGENOMI INCsh$6,029,216
-67.2%
1,477,749
-15.3%
0.08%
-65.8%
TARA NewPROTARA THERAPEUTIC INCsh$3,952,0001,900,000
+100.0%
0.05%
NewSURROZEN INCsh$3,094,251282,580
+100.0%
0.04%
 NEWAMSTERDAM PHARMA CO NV-27sh$2,906,664
-21.0%
333,3330.0%0.04%
-19.1%
SellUNICYCIVE THERAPEUTICS INCsh$1,318,995
-72.5%
2,632,200
-24.2%
0.02%
-72.1%
NewSCILEX HOLDING COsh$504,075261,179
+100.0%
0.01%
CVAC ExitCUREVAC NVsh$0-1,965,707
-100.0%
-0.08%
CMPS ExitCOMPASS PATHWAYS PLCsh$0-791,359
-100.0%
-0.08%
IGMS ExitIGM BIOSCIENCES INCsh$0-937,500
-100.0%
-0.12%
BDTX ExitBLACK DIAMOND THERAPEUTICS Ish$0-3,525,754
-100.0%
-0.23%
EYPT ExitEYEPOINT PHARMACEUTICALS INCsh$0-938,591
-100.0%
-0.25%
VXRT ExitVAXART INCsh$0-15,384,615
-100.0%
-0.25%
ExitCYTEK BIOSCIENCES INCsh$0-6,809,404
-100.0%
-0.58%
MDGL ExitMADRIGAL PHARMACEUTICALS INCsh$0-204,500
-100.0%
-0.70%
INBX ExitINHIBRX INCsh$0-2,629,837
-100.0%
-1.17%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2024-08-14
Signatures

The EDGAR filing(s) were signed by:

About RA Capital Management

RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.

The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.

RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.

Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.

Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ASCENDIS PHARMA A/S - ADR38Q2 202425.5%
WAVE LIFE SCIENCES PTE LTD35Q2 202426.3%
TG THERAPEUTICS INC30Q4 20216.3%
ZOGENIX INC26Q4 20219.5%
RHYTHM PHARMACEUTICALS INC25Q2 20244.4%
BIOCRYST PHARMACEUTICALS23Q1 20199.2%
DICERNA PHARMACEUTICALS INC23Q3 20195.8%
ACHILLION PHARMACEUTICALS INC19Q4 201717.2%
89BIO INC19Q2 20244.1%
KALA PHARMACEUTICALS INC19Q1 20224.4%

View RA Capital Management's complete holdings history.

Latest significant ownerships (13-D/G)
RA Capital Management Q2 2024 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Perceptive Capital Solutions CorpJune 24, 2024750,0008.4%
Aerovate Therapeutics, Inc.June 20, 20249,242,09232.0%
Evolent Health, Inc.June 17, 20248,279,1037.1%
Solid Biosciences Inc.June 12, 20244,358,47811.3%
BICYCLE THERAPEUTICS plcJune 07, 20242,253,0005.0%
Tourmaline Bio, Inc.June 03, 20242,045,0288.0%
Structure Therapeutics Inc.May 30, 20247,225,3115.2%
iTeos Therapeutics, Inc.May 14, 20243,659,04610.0%
Medicenna Therapeutics Corp.May 10, 20247,714,76010.0%
Black Diamond Therapeutics, Inc.May 09, 20242,788,0285.0%

View RA Capital Management's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D/A2024-10-01
32024-09-23
SC 13D2024-09-23
42024-09-18
42024-09-16
SC 13D/A2024-09-16
SC 13G/A2024-09-16
32024-09-12
SC 13D/A2024-09-03
N-PX2024-08-30

View RA Capital Management's complete filings history.

Compare quarters

Export RA Capital Management's holdings